Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales lost to patent expirations.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In an interview Friday during ...

FRANKFURT (Reuters) -Bayer has told U.S. lawmakers it could stop selling Roundup weedkiller unless they can strengthen legal protection against product liability litigation, according to a financial ...

FRANKFURT, March 7 (Reuters) - Bayer (BAYGn.DE), opens new tab told several brokerages about plans to seek shareholder permission to issue shares one day before formally announcing the news on Friday, ...

Bayer announced July 30 that it has submitted applications in four major agricultural markets—the European Union, Brazil, Canada, and the United States—for a new herbicide with a new mode of action, ...